Liver cancer is the fifth most common cancer in the world, with hepatocellular carcinoma (HCC) accounting for most. The only treatment available is surgery. However, less than 20% of HCC can be removed completely by surgery. Moreover, most patients are not diagnosed until their cancer is advanced. As a result, the median survival following diagnosis is only 6 to 20 months.
Researchers at VCU have shown that overexpression of Late SV40 Factor (LSF) contributes to the pathogenesis of heptacellular carcinoma (HCC). Not only was LSF overexpression observed in over 90% of patients, its expression level correlated with the stage and grade of HCC. LSF plays a critical role in HCC by modulating genes that regulate invasion, angiogenesis, chemoresistance and senescence.
Thus, LSF represents a novel target for HCC therapy. In addition, measurement of LSF expression might be used as a prognostic marker for HCC.
U.S. patent pending: 13/636,815
For more information please see journal article: Yoo et al. PNAS 2010;107 (18): 8357-62
This technology is available for licensing to industry for further development and commercialization.